What insurance policy changes affect HCPCS J3403?

There are 17 tracked policy changes affecting HCPCS J3403, including updates from Anthem BCBS, Blue Cross Blue Shield of Rhode Island, Harvard Pilgrim Health Care. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J3403?

Payers that have issued tracked updates for HCPCS J3403 include: Anthem BCBS, Blue Cross Blue Shield of Rhode Island, Harvard Pilgrim Health Care, Texas Medicaid, Kansas Medicaid (KanCare), Michigan Medicaid - MDHHS, Molina Healthcare, Blue Cross & Blue Shield of Mississippi.

How do I get notified when HCPCS J3403 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J3403. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J3403?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J3403 — Revakinagene taroretcel-lwey, per implant: Insurance Policy Changes

J3403 Insurance Policy Changes

HCPCS J3403 is officially defined as "Revakinagene taroretcel-lwey, per implant." HCPCS J3403 is referenced in 17 tracked payer policy changes from Anthem BCBS, Blue Cross Blue Shield of Rhode Island, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3403 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

[New York] March 2026 Provider Newsletter

Anthem BCBS·Effective Apr 1, 2026

This is a March 2026 provider newsletter from Anthem summarizing multiple administrative, educational, and policy updates across New York commercial, Medicare Advantage, and Medicaid plans. Key billing-related changes include: (1) Prior authorization requirement changes effective April 1, 2026 for Medicaid and June 1, 2026 for Commercial (codes 64595, J3402, J3403); (2) Modifier 26 (professional services) billing changes on UB-04 for outpatient facilities effective April 1, 2026; (3) Bundled services/supplies reimbursement policy updates effective June 1, 2026; (4) MCG Care Guidelines 30th edition updates effective June 1, 2026; and (5) New MLTC fax numbers and dispute submission process changes effective March 1, 2026.

J3403 Insurance Policy Changes

[New York] March 2026 Provider Newsletter

Additional HCPCS Level II Code Changes and Modifier Changes

[New York] Precertification/prior authorization list change notification

[California] Prior authorization requirement changes

[Virginia] Precertification/prior authorization list change notification

[Georgia] Precertification/prior authorization requirement changes

[Georgia] Precertification/prior authorization list change notification

[New York] Prior authorization requirement changes

[Virginia] March 2026 Provider Newsletter

Point32Health medical drug program updates

Additional Provider Types Added for Revakinagene Taroretcel-lwey (Encelto), Procedure Code J3403

KMAP BULLETIN: HCPCS Codes Updates – October 2025

MMP 25-46: Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Code Updates

Point32Health medical drug program updates

Prior Authorization Requests Effective 10/1/25

State and School Employees' Health Insurance Plan - Encelto (revakinagene taroretcel-lwey)

Encelto (revakinagene taroretcel-lwey)